Inc. (NASDAQ: INMB) (the “Company”), a clinical-stage inflammation and immunology company targeting microglial activation and neuroinflammation as a cause of Alzheimer’s Disease (AD), announced today ...
Mark Lowdell, CSO and inventor of INKmune™, said, “The enrollment of the first cohort ran entirely in-line with our predicted timelines and confirmed the excellent safety profile with all patients ...